On June 1, WuXi Biologics rose 3.06% in regular trading, trading at HKD 35.06 per share, with trading volume of HKD 193 million.

On the news front, the company's previously announced share buyback plan of up to USD 400 million continues to be executed. From May 27 to May 29, the company repurchased over 4.5 million shares across three consecutive trading days, spending approximately HKD 150 million in aggregate. Meanwhile, the company disclosed that it added 69 new integrated projects in the first four months, maintaining its full-year revenue growth guidance of 13% to 17% year-over-year. A business update conference call was also held on June 1.

Additionally, the company's 18th drug product manufacturing facility has received GMP clearance and commenced operations, further strengthening its end-to-end integrated capacity from drug substance to drug product. The sustained buyback execution, coupled with robust new project additions and capacity expansion, continues to reinforce market confidence in the company's long-term growth trajectory.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)